ADAG Adagene Corp: Bathi resik saben saham sajrone 12 wulan pungkasan

Adagene is developing a unique NEObody monoclonal antibody platform, securing its rights through protein masking patents for licensing to industry behemoths. This price action on GURU.Markets reflects an EPS of 41.50. The company minimizes plant expenditures by utilizing external contractors for testing and mitigates risks through partnerships in IT therapy design.
Adagene - rincian analitis lan metrik utama (ADAG)

Year-over-year EPS (TTM) growth measures the dynamics of net profit per share, reflecting the efficiency of business capitalization while accounting for the discounting of flows at the WACC rate. By analyzing this annual EPS TTM chart, an investor assesses the financial stability of Adagene (ADAG) amid strict FDA oversight and the impact of SAFEbody patents on the company's market value.